Comparative efficacy of doripenem versus meropenem for ... | 全球疫情雷達
由WDLiu著作·2019·被引用19次—However,theuseofdoripenemforhospital-acquiredpneumonia(HAP)andventilator-associatedpneumonia(VAP)remainscontroversial.Theaimofthisstudywas ...
Background: Doripenem shows good in vitro activity against common nosocomial pathogens, such as extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii. However, the use of doripenem for hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) remains controversial. The aim of this study was to compare the efficacy and safety between doripenem and meropenem for patients with HAP or VAP.
Methods: Adult patients diagnosed with HAP and VAP at National Taiwan University Hospital, who received doripenem or meropenem for more than 48 h between January 2015 and November 2017, were retrospectively reviewed. All-cause mortality on the 30th day was used as the primary outcome measurements.
Results: Fifty-seven patients with doripenem and 252 patients with meropenem were analyzed. Compared to the meropenem group,...
Comparative efficacy of doripenem versus meropenem for ... | 全球疫情雷達
Doripenem for treating nosocomial pneumonia ... | 全球疫情雷達
Doripenem in the Treatment of Patients with ... | 全球疫情雷達
[FDA警訊]Doripenem用於呼吸器相關肺炎可能增加死亡率 ... | 全球疫情雷達
使用含doripenem(藥品名Finibax)成分藥品之用藥資訊 | 全球疫情雷達
新一代carbapenem類抗生素:Doripenem | 全球疫情雷達
抗碳青黴烯類腸桿菌屬(CRE)超級細菌 2021/2/25 通報,發生國家:韓國
韓國衛生部公布忠清南道2020年累計通報331例,其中88%檢驗為陽性,病例中逾65%為70歲以上老年人口;該地區近3年病例數逐年上...
廣泛抗藥性大腸桿菌 2021/7/23 通報,發生國家:歐洲及英國
ECDC於7/20公布,新增3國報告病例,自2/18迄今累計通報370例感染具碳青黴烯抗藥性之大腸桿菌OXA-244ST38,其中210例來自英國...